> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Jennison Associates Takes A 5.5% Passive Stake In Rezolute, Holding 5.3 Million Shares
- URL: https://www.bullished.co/jennison-associates-takes-a-5-5-passive-stake-in-rezolute-holding-5-3-million-shares-2ac28d6a/
- Published: 2026-10-28T20:12:25.000Z
- Updated: 2026-11-05T19:45:53.000Z
- Description: The New York investment adviser holds 5,332,068 shares of the rare-disease drug developer, with an event date of September 30.
- Author: Matteo Parrino
- Tags: SEC Filings, RZLT, Industry: Healthcare

Jennison Associates, a New York investment adviser, holds [5,332,068 shares](https://www.sec.gov/Archives/edgar/data/0000053417/000005341726000065/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Rezolute](https://www.bullished.co/tag/rzlt/), or 5.5% of the common stock, according to a passive ownership disclosure filed Wednesday. The position is dated September 30.

## Sole control over every share

Jennison reported sole voting power and sole dispositive power (the power to sell) [over all 5,332,068 shares](https://www.sec.gov/Archives/edgar/data/0000053417/000005341726000065/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), with no shared voting power. It listed itself as an investment adviser.

The 5.5% is a cover-page percentage. Under SEC rules it counts any warrants, options or convertibles the holder could exercise within 60 days, in both the holding and the share base.

Jennison certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Rezolute.

## A rare-disease drug developer with no product

Rezolute, based in Redwood City, California, is a late-stage rare disease company developing therapies for refractory hypoglycemia, or dangerously low blood sugar, linked to hyperinsulinism, a condition of excess insulin activity. Its lead candidate, ersodetug, is an intravenous antibody being studied in congenital hyperinsulinism, which affects children, and in hyperinsulinism caused by tumors.

The company has no approved products. It also runs an expanded access program that supplies ersodetug to patients who cannot join a clinical trial.

Its 10-K for the fiscal year ended June 30, 2026 puts research and development spending at about $53.8 million for the year. As of that date it had 58 full-time employees, all in the United States, 40 of them in research and development. Rezolute's market capitalization was $398 million in Wednesday trading.

Jennison's filing lists 275 Shoreline Drive in Redwood City as Rezolute's address and 55 East 52nd Street in New York as its own.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Jennison Associates LLC re: REZOLUTE INC (RZLT)](https://www.sec.gov/Archives/edgar/data/0000053417/000005341726000065/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Rezolute

- [Rezolute Sizes Tumor Hyperinsulinism At $4-5 Billion, With Patients Needing Triple The Vials](https://www.bullished.co/rezolute-sizes-tumor-hyperinsulinism-at-4-5-billion-with-patients-needing-triple-the-vials-c8adbb53/)
- [Rezolute's CEO Took Home $5,711,410 And Also Chairs The Board, Proxy Shows](https://www.bullished.co/rezolutes-ceo-took-home-5-711-410-and-also-chairs-the-board-proxy-shows-61925309/)
- [Rezolute Finishes Enrolling 16-Patient Tumor Hyperinsulinism Trial, Expects Topline Data Mid-December](https://www.bullished.co/rezolute-finishes-enrolling-16-patient-tumor-hyperinsulinism-trial-expects-topline-data-5dc3335f/)

[All Rezolute (RZLT) coverage →](https://www.bullished.co/tag/rzlt/)